维普中文期刊产品整合服务
201篇 您的检索式:作者名="HUDY"
    题名 作者 年代 出处 被引量
1Targeting p53 pathways:mechanisms,structures,and advances in therapy显示文摘The TP53 tumor suppressor is the most frequently altered gene in human cancers,and has been a major focus of oncology research.The p53 protein is a transcription factor that can activate the expression of multiple target genes and plays critical roles in regulating cell cycle,apoptosis,and genomic stability,and is widely regarded as the“guardian of the genome”.Accumulating evidence has shown that p53 also regulates cell metabolism,ferroptosis,tumor microenvironment,autophagy and so on,all of which contribute to tumor suppression.Mutations in TP53 not only impair its tumor suppressor function,but also confer oncogenic properties to p53 mutants.Since p53 is mutated and inactivated in most malignant tumors,it has been a very attractive target for developing new anti-cancer drugs.However,until recently,p53 was considered an“undruggable”target and little progress has been made with p53-targeted therapies.Here,we provide a systematic review of the diverse molecular mechanisms of the p53 signaling pathway and how TP53 mutations impact tumor progression.We also discuss key structural features of the p53 protein and its inactivation by oncogenic mutations.In addition,we review the efforts that have been made in p53-targeted therapies,and discuss the challenges that have been encountered in clinical development.Haolan Wang Ming Guo Hudie Wei Yongheng Chen 2023Signal Transduction and Targeted Therapy2023,8,4:4
2Distribution of perfluorinated compounds in surface water from Hanjiang River in Wuhan, China显示文摘Beibei Wang Menghua Cao Hudi Zhu Jing Chen Linling Wang Guanghong Liu Xiaoman Gu Xiaohua Lu 2013Chemosphere2013,,:2
3Sugar uptake and utilisation during adventitious bud differentiation on in vitro leaf explants of 'Wegierka Zwykla'plum(Prunus domestica)显示文摘Nowak B Miczynski K Hudy L 2004Plant Cell Tissue and Organ Culture2004,76,:1
4Cardiac dysfunction in the trastuzumab clinical trials experience显示文摘Seidman A Hudis C Pierri MK 2002J Clin Oncol2002,20,5:1
5Progesterone - induced blocking factor (PIBF) and Th ( 1 )/Th (2) cytokine in women with threatened spontaneous abortion显示文摘Hudi$ I Fatusi$ Z 2009J Perinat Med2009,37,4:1
6Potential role of selective COX-2 inhibitors in cancer management显示文摘Dang CT Shapiro CL Hudis CA 2002Oncology2002,16,:1
7Chemicalconstituentsofhw/eracig炉’ego如显示文摘ZHUYZ LIUMC HUDY etal 2012中国实验方剂学杂志2012,18,16:1
8Advances in adjuvant chemotherapy of early stage breast cancer显示文摘McArthur H L and Hudis C A 2008Cancer Treat Res2008,141,:1
9Cardiac dysfunction in the trastuzumab clinical trials experience显示文摘Seidman A Hudis C Pierri MK 2002J Clin Oncol2002,20,5:1
10American society of clinical oncology technology assessment on the use of aromotase inhibitors as adjuvant theraphy for postmenopausal women with hormone receptor-positive breast cancer:status report 2004显示文摘Winer EP Hudis C Burstein HJ 2005J Clin Oncol2005,23,3:1
11Phase Ⅱ evaluation of taxotere (RP 56976, NSC 628503) as initial chemotherapy for metastatic breast cancer 显示文摘Seidman AD Hudis C Crown JPA 1993Proc Am Soc Clin Oncol1993,12,:1
12American society of clinic-oncology technology assessment on the use of aromotasein hibitors as adjuvant theraphy for postmenopausal women with hormone receptor-positive breast cancer status report显示文摘Winer EP Hudis C Burstein HJ 2005ClinOncol2005,23,3:1
13Trastuzumab: mechanism of action and use in clinical practice显示文摘Hudis CA 2007N Engl J Med2007,357,1:1
14Trastuzumab-mechanism of action and use in clinical practice显示文摘Hudis CA 2007New Engl J Med2007,357,1:1
15Overall Job Satisfaction:How Good Are Single-item Measures?显示文摘 REICHERS A E HUDY M J 1997Journal of Applied Psychology1997,82,2:1
16American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer:Status report 2004显示文摘Winer EP Hudis C Burstein HJ 2005J Clin Oncol2005,23,3:1
17Trastuzumab-mechanism of action and use inclinical practice 显示文摘Hudis CA 2007N Engl J Med2007,357,1:1
18Trastuzumab-mechanism of action and use in clinical practice显示文摘Hudis CA 0,,01:1
19A phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HEP,2-negative breast cancer (the resilience study ): study protocol for a randomized controlled trial 显示文摘Baselga J Costa F Gomez H Hudis CA Rapoport B Roche H Schwartzberg LS Petrenciuc O Shan M Gradishar WJ 2013Trials2013,14,:1
20New approaches to adjuvant chemotherapy for breast cancer显示文摘Hudis C 1996Pharmaco Therapy1996,16,32:1
返回顶部 每页显示:
共11页 首页 上一页 第1页 下一页 末页 /11 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费